Biotest Pharmaceuticals names new chief executive

Jordan Siegel is promoted from chief financial officer

Jordan Siegel will become chief executive of Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG of Dreieich, Germany, on 1 May.

BPC’s interim chief executive, Georg Floss, will return to Germany on 30 April to assume the role of global head of operations at Biotest AG.

Siegel has been BPC’s senior vice president, finance and chief financial officer since its inception in 2007.

BPC researches, develops and manufactures biotherapeutic products for immunology and haematology. The firm is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. It owns and manages 12 plasmapherisis centres across the US and a manufacturing facility in Boca Raton, Florida.

You may also like

Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Manufacturing

Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases

Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
Media

UK REACH reform falls short as industry warns of £500m+ compliance bill

The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
Manufacturing

Freudenberg Medical launches CleanAssure ISO Class 5 cleanroom service for sterile single-use biopharma assemblies

CleanAssure is an ISO Class 5 controlled cleanroom service delivering washed, dried and gamma-sterilised single-use assemblies to biopharmaceutical customers, addressing industry challenges around cleaning validation and contamination risk
Manufacturing

Mabwell signs Malaysia licensing deal for denosumab biosimilars MAILISHU and MAIWEIJIAN

Mabwell has entered a licensing and commercialisation agreement to bring its denosumab biosimilars to Malaysia, supporting regional access through local registration and supply of its Prolia and Xgeva reference products
Subscribe now